Monitor for any new acquisition or licensing agreements that may replace the terminated LOI, and watch for any impact on the company's ability to execute its technology integration plans.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 5 $1.22entry
- T+1 · 5d ago −3.28%α −3.59% · $1.18
- T+3 · todayOpen
- T+5 · tomorrow Pending
- T+20 · in 23d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
DataMeds AI terminated its Second Amended and Restated Letter of Intent with multiple counterparties for the in-license or acquisition of IP in exchange for common stock, citing market conditions. No fees or obligations are owed, and no shares will be issued under the terminated LOI. Existing license agreements with REBOOT and Datavault remain in effect.
Key Facts
- LOI terminated effective November 3, 2026, due to market conditions.
- No fees or obligations owed by DataMeds as a result of termination.
- No shares will be issued in connection with the terminated LOI.
- Exclusive license with REBOOT for GLP-1 user management remains in effect.
- Datavault AI PharmacyChain license agreement remains in full force and effect.
- Market cap is $9M; normal daily move is 10.1%.
Financial Impact
No stated financial impact; no fees or termination payments. Avoided potential dilution from share issuance for IP acquisition.
Risk Factors
- Termination may delay or prevent the acquisition of key IP assets, potentially weakening competitive positioning.
- No alternative transactions have been announced, creating uncertainty around growth strategy.
- Existing license agreements remain, but the broader strategic plan may need revision.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-050033 |
| Exhibit: ex99-1.htm | 0001493152-26-050033 |
| Document: 0001493152-26-050033-index-headers.html | 0001493152-26-050033 |
| Document: 0001493152-26-050033-index.html | 0001493152-26-050033 |
| Document: 0001493152-26-050033.txt | 0001493152-26-050033 |
Track record
10 reports on MEDS
2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +12.62% at T+5 after the Oct 26, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 10, 2026today SC 13G Neutral 4/10 Entry $1.04 Now $0.8963 −13.82% settles Nov 18
- Nov 10, 2026today S-1/A Bearish 6/10 Entry $1.04 Now $0.8963 +13.82% settles Nov 18
- Nov 5, 20265d ago 8-K Neutral 4/10 Viewing Entry $1.22 Now $0.8963 −26.53% settles Nov 12
- Oct 26, 202615d ago 8-K Bearish 6/10 Entry $2.06 to $1.80 Now $0.8963 +56.49% ▲ +12.62% +10.63% vs SPY
- Oct 20, 202621d ago 8-K Neutral 4/10 Entry $2.75 to $2.06 Now $0.8963 −67.41% ▼ −25.09% −25.17% vs SPY
- Oct 16, 202625d ago 8-K Mixed 6/10 Entry $2.67 to $2.20 Now $0.8963 −66.43% ▼ −17.60% −17.46% vs SPY
- Oct 13, 202628d ago 8-K Mixed 5/10 Entry $2.85 to $2.72 Now $0.8963 −68.55% ▼ −4.56% −5.01% vs SPY
- Sep 17, 20267w ago 8-K Bullish 6/10 Entry $3.76 to $3.11 Now $0.8963 −76.16% ▼ −17.29% −18.56% vs SPY
- Sep 16, 20267w ago 8-K Neutral 5/10 Entry $4.64 to $3.50 Now $0.8963 −80.68% ▼ −24.57% −25.17% vs SPY
- Aug 18, 202612w ago 8-K Bearish 7/10 Entry $1.38 to $1.36 Now $0.8963 +35.05% ▲ +1.45% +1.25% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers